Which medication is commonly used to treat narcolepsy?

Prepare for the EDAPT Intracranial Regulation Test with interactive flashcards and multiple choice questions. Each question is accompanied by helpful hints and explanations to boost your readiness. Get started today and ensure your success!

Multiple Choice

Which medication is commonly used to treat narcolepsy?

Explanation:
Narcolepsy is marked by excessive daytime sleepiness due to a failure of the brain’s wake-promoting systems to sustain alertness. The goal of treatment is to boost wakefulness during the day. Modafinil is commonly used for this purpose because it effectively promotes wakefulness with a lower risk of abuse and fewer stimulant-related side effects than traditional stimulants. It provides reliable daytime alertness and is often chosen as a first-line option for narcolepsy-related daytime sleepiness. Stimulants like methylphenidate or amphetamine can also help with alertness, but they carry higher potential for abuse, cardiovascular side effects, and insomnia. Selegiline, an MAO-B inhibitor used in Parkinson’s disease, isn’t a standard treatment for narcolepsy and isn’t effective for promoting daytime wakefulness in this context.

Narcolepsy is marked by excessive daytime sleepiness due to a failure of the brain’s wake-promoting systems to sustain alertness. The goal of treatment is to boost wakefulness during the day. Modafinil is commonly used for this purpose because it effectively promotes wakefulness with a lower risk of abuse and fewer stimulant-related side effects than traditional stimulants. It provides reliable daytime alertness and is often chosen as a first-line option for narcolepsy-related daytime sleepiness.

Stimulants like methylphenidate or amphetamine can also help with alertness, but they carry higher potential for abuse, cardiovascular side effects, and insomnia. Selegiline, an MAO-B inhibitor used in Parkinson’s disease, isn’t a standard treatment for narcolepsy and isn’t effective for promoting daytime wakefulness in this context.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy